Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.60
Bid: 18.60
Ask: 18.98
Change: -0.07 (-0.37%)
Spread: 0.38 (2.043%)
Open: 20.00
High: 20.00
Low: 18.60
Prev. Close: 18.86
NANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Litigation Funding Agreement

13 Jul 2020 07:00

RNS Number : 7309S
Nanoco Group PLC
13 July 2020
 

FOR IMMEDIATE RELEASE 13 July 2020

Nanoco Group PLC

 

("Nanoco", the "Group", or the "Company")

 

Litigation Funding Agreement

 

Agreement funds patent infringement lawsuit against Samsung

 

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials emanating from its technology platform, today announces that it has signed a Litigation Funding Agreement ('LFA' or 'Agreement') with a very large U.S. litigation finance specialist with extensive experience in financing technology-based IP patent litigation matters (the 'Funder').

 

On 17 February 2020, the Group announced that it had filed a patent infringement lawsuit against various Samsung entities in the United States District Court for the Eastern District of Texas. The lawsuit claims infringement of a number of Nanoco's U.S. patents which relate to Nanoco's unique synthesis and resin capabilities for quantum dots. Nanoco retained Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. ('Mintz'), an international IP law firm based in Boston, Massachusetts, USA, to represent it in patent enforcement and litigation. Ward, Smith & Hill, PLLC, an IP law firm based in Longview, Texas, USA, was retained to act as local counsel.

 

Under the LFA, the Funder will fund the costs of the litigation against Samsung. The LFA removes the funding burden for the suit from Nanoco and its shareholders. In return, the Funder can expect to receive a multiple of their invested capital in the event of a settlement or judgement in favour of Nanoco. Patent infringement cases can take 2 years or more to get to trial and cost many millions of dollars to prosecute.

 

The Board is confident in the strength of Nanoco's IP portfolio and the suit against Samsung. Damages models indicate that the Group will retain the majority of any financial award or settlement and the Group's relative and absolute share of any award will increase with the size of the overall award.

 

Dr Michael Edelman, Nanoco's CEO, commented:

 

"We are particularly pleased to be working with IP lawyers and a Funder who have strong and established track records for successfully pursuing patent infringement cases, including against Samsung. The successful outcome of their extensive and detailed due diligence, including the use of independent experts, adds to our significant confidence in our case against Samsung for what we believe to be their willful infringement of our intellectual property. This follows on from the similarly detailed due diligence performed by our strategic adviser (Epicentre IP Group LLC) and litigation counsel (Mintz).

 

"With third party funding for the costs of the litigation, alongside our recently announced agreement with STMicroelectronics underpinning our cash runway through the second quarter of 2021, we now have a platform on which to deliver new commercial business wins and further extend our cash runway while actively pursuing this lawsuit against Samsung."

 

- Ends -

For further information, please contact:

Nanoco Group PLC:

Michael Edelman, CEO +44 (0) 161 603 7900

Brian Tenner, COO & CFO +44 (0) 161 603 7900

Caroline Watson, Investor Relations Manager +44 (0) 7799 897 357

cwatson@nanocotechnologies.com

 

Peel Hunt:

Edward Knight +44 (0) 20 7418 8900

Nick Prowting

 

MHP Communications: +44 (0) 203 128 8570

Reg Hoare

Giles Robinson

Pete Lambie

nanoco@mhpc.com

 

The person responsible for arranging for the release of this announcement on behalf of Nanoco is Brian Tenner, Chief Financial Officer.

MAR

The information contained within this announcement is considered by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information will be considered to be in the public domain.

FORWARD LOOKING STATEMENTS

This announcement (including information incorporated by reference in this announcement) and other information published by Nanoco may contain statements about Nanoco that are or may be deemed to be forward looking statements. Such statements are prospective in nature. All statements other than historical statements of facts may be forward looking statements. Without limitation, statements containing the words "targets", "plans", "believes", "expects", "aims", "intends", "will", "may", "anticipates", "estimates", "projects" or "considers" or other similar words may be forward looking statements.

Forward looking statements inherently contain risks and uncertainties as they relate to events or circumstances in the future. Important factors such as business or economic cycles, the terms and conditions of Nanoco's financing arrangements, tax rates, or increased competition may cause Nanoco's actual financial results, performance or achievements to differ materially from any forward looking statements. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward looking statements, which speak only as of the date hereof. Nanoco disclaims any obligation to update any forward looking or other statements contained herein, except as required by applicable law.

Notes for editors:

About Nanoco Group plc

Nanoco (LSE: NANO) harnesses the power of nano-materials. Nano-materials are materials with dimensions typically in the range 1 - 100 nm. Nano-materials have a range of useful properties, including optical and electronic. Quantum dots are a subclass of nano-material that have size-dependent optical and electronic properties. The Group produces quantum dots. Within the sphere of quantum dots, the Group exploits different characteristics of the quantum dots to target different performance criteria that are attractive to specific markets or end-user applications such as the Display and Electronics markets. One of the interesting properties of quantum dots is photoluminescence: the emission of longer wavelength light upon excitation by light of a shorter wavelength. The colour of light emitted depends on the particle size. Nanoco's CFQD® quantum dots are free of cadmium and other toxic heavy metals and can be tuned to emit light at different wavelengths across the visible and infrared spectrum, rendering them useful for a wide range of applications including displays, lighting and biological imaging.

Nanoco was founded in 2001 and is headquartered in Manchester, UK, with a US subsidiary, Nanoco Inc., in Concord, MA. Nanoco continues to build out a world-class, patent-protected IP portfolio generated both by its own innovation engine, as well as through acquisition.

Nanoco is listed on the Main Market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocotechnologies.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRFBLLFBDLXBBZ
Date   Source Headline
25th Jul 20232:55 pmRNSPublication of Shareholder Presentation
25th Jul 202312:52 pmRNSNanoco Group Plc
24th Jul 20237:00 amRNSHigh Court Confirmation of Capital Reduction
20th Jul 20237:00 amRNSNotification of Investor Presentation
18th Jul 20237:00 amRNSPosting of Circular and Notice of General Meeting
7th Jul 202311:23 amRNSGeneral Meeting - Voting Results
28th Jun 20237:00 amRNSReceipt of General Meeting Requisition Notice
20th Jun 20237:00 amRNSPosting of Circular and Notice of General Meeting
9th Jun 20237:00 amRNSBlocklisting Six-Monthly Return
19th May 20231:00 pmRNSResponse to Shareholder Letter
21st Apr 20236:00 pmRNSHolding(s) in Company
30th Mar 202311:46 amRNSHolding(s) in Company
28th Mar 20237:00 amRNSInterim Results
27th Mar 20231:19 pmRNSResponse to Shareholder Letter
23rd Mar 20238:40 amRNSNotice of Results
9th Mar 20233:11 pmRNSHolding(s) in Company
9th Feb 20237:00 amRNSDirector/PDMR Shareholding
7th Feb 20237:00 amRNSHolding(s) in Company
3rd Feb 20237:15 amRNSTrading Update
3rd Feb 20237:15 amRNSLitigation Settlement Update
18th Jan 202311:35 amRNSHolding(s) in Company
16th Jan 202312:45 pmRNSHolding(s) in Company
11th Jan 20232:40 pmRNSHolding(s) in Company
10th Jan 20232:37 pmRNSHolding(s) in Company
9th Jan 20237:00 amRNSLitigation Settlement Update
6th Jan 20237:00 amRNSLitigation Outcome – Settlement Agreed
4th Jan 20233:31 pmRNSHolding(s) in Company
20th Dec 20223:51 pmRNSHolding(s) in Company
20th Dec 20222:59 pmRNSResult of AGM
20th Dec 20227:00 amRNSAGM Statement
13th Dec 20227:00 amRNSBlock listing Six-monthly Return
9th Dec 20227:00 amRNSLitigation Update - Firm Trial Date
14th Nov 202210:46 amRNS2022 Annual Report and Notice of AGM
7th Nov 20224:13 pmRNSHolding(s) in Company
27th Oct 20225:19 pmRNSDirector/PDMR Shareholding
26th Oct 20222:31 pmRNSLitigation Update – Funded Law Suit Filed in China
20th Oct 20227:00 amRNSPreliminary Results
14th Oct 202212:59 pmRNSPresentation via Investor Meet Company
14th Oct 202210:41 amRNSNotice of Results
28th Sep 20227:00 amRNSLitigation Update – Further Revised Trial Date
12th Sep 20228:25 amRNSTrading Update & Directorate Change
7th Sep 20223:47 pmRNSLitigation Update – Revised Trial Date
1st Sep 202210:22 amRNSDirector/PDMR Shareholding
31st Aug 20227:00 amRNSTwo Grant Funding Awards
30th Aug 20223:33 pmRNSHolding(s) in Company
30th Aug 20223:28 pmRNSDirector/PDMR Shareholding
25th Aug 20221:36 pmRNSDirector/PDMR Shareholding
23rd Aug 20222:22 pmRNSFunded Law Suit Filed in Germany
19th Aug 20228:21 amRNSLitigation Update – Pre-Trial Conference
18th Aug 20224:10 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.